This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
The novel CDK12/13 inhibitor SR-4835 was effective in mouse models of triple-negative breast cancer.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
Published OnlineFirst November 1, 2019
doi: 10.1158/2159-8290.CD-RW2019-164
CDK12/13 Inhibitor SR-4835 Is Active in Triple-Negative Breast Cancer
Jump to section
Advertisement